Chemomab Therapeutics Ltd - ADR
CMMB
Market Cap$1.34M
Close$
$0.35
71.2% downside
Current Fair Value
71.2% downsideOvervalued by 71.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.34 Million |
|---|---|
| Enterprise Value | $-4,408,181.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.02 |
| Beta | 0.67 |
| Outstanding Shares | 942,830 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.1 |
|---|---|
| PEG | 0.67 |
| Price to Sales | - |
| Price to Book Ratio | 0.09 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.29 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.07 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Chemomab Therapeutics Ltd
2,020 employeesChemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in pr...